Winterlight Labs
Winterlight Labs, founded in 2015 in Toronto, Canada, develops tablet-based assessments to detect cognitive impairment using speech analysis, trusted by leading Life Sciences companies and used in numerous clinical trials.
Winterlight Labs Founders
Winterlight Labs was founded in 2015 in Toronto, Canada. The founders developed a unique tablet-based technology that assesses cognitive health by analyzing hundreds of language markers from short snippets of speech. Since its inception, the company has grown rapidly, gaining recognition for its innovative approach to detecting cognitive impairment and its partnerships with leading life sciences companies and research institutions.
Winterlight Labs Technology
Winterlight Labs uses proprietary technology that extracts speech-based digital biomarkers from short snippets of speech. This technology detects cognitive impairment associated with dementia and mental illness and automates clinical assessment administration and scoring. The system leverages natural language processing and artificial intelligence to analyze over 550 features of speech and language, allowing for the measurement of fine-grained changes often missed by traditional assessments. The technology is trusted by top life sciences companies and is instrumental in multiple clinical trials.
Winterlight Labs Partnerships
Winterlight Labs has several key partnerships that bolster its mission of improving disease detection and monitoring through speech analysis. Notable collaborations include Genentech, with whom they demonstrated the sensitivity of speech-based digital measures in detecting changes in Alzheimer's disease, and Alzheimer Center Amsterdam, where they are decentralizing patient assessments in preclinical Alzheimer's research. These partnerships extend the reach of Winterlight Labs' technology and contribute to advancing clinical research.
Winterlight Labs Clinical Trials and Research
Winterlight Labs' assessment technology is employed in a dozen clinical trials to track changes in cognitive health and identify treatment responses. These trials encompass a range of neurodegenerative and psychiatric diseases, including Alzheimer's Disease, Mild Cognitive Impairment, Frontotemporal Dementia, Parkinson’s Disease, Depression, and Schizophrenia. The company's research also extends to speech patterns across different ages to enhance their disease detection tools.
Winterlight Labs Speech Analysis API
Winterlight Labs offers a speech analysis API, designed to receive analyses for speech data or integrate with apps or devices that collect continuous speech. This API extends the company's reach by allowing partners and developers to incorporate their speech-based biomarkers into various applications and platforms, facilitating real-time monitoring and assessment of cognitive impairments and neurological changes.